Hamlet Pharma has signed an agreement concerning the clinical phase II study of HAMLET and the therapeutic effects on bladder cancer.
Professor Marek Babjuk has agreed to serve as the clinical study coordinator and his unit at the Charles University and the Motol University Hospital in Prague will perform the study. Professor Babjuk is chairman of the European bladder cancer society and has extensive experience in conducting clinical trials in bladder cancer and other urological indications. The center will participate in study design, prepare ethical documentation and recruit the patients.
After completion of the study, he will evaluate the clinical outcome of the study. Molecular end points will be evaluated at Lund University. Finally, Professor Babjuk will sit on the scientific advisory board, which is formed by Hamlet Pharma for this study.
Hamlet Pharma AB owns and develops a new technology to kill cancer cells without harming healthy tissues. The HAMLET technology is focused around the HAMLET family of tumoricidal protein-lipid complexes, formed by naturally occurring molecules from human milk and extended to include recombinant variants of the natural substance. HAMLET has validated therapeutic efficacy in clinical studies and animal models, and in many different cellular models of human cancer. HAMLET will now be developed further for Phase II clinical trials, to verify the positive proof of concept studies. Hamlet Pharma AB shares are listed at AktieTorget. HAMLET is an abbreviation for Human Alpha-lactalbumin Made LEthal to Tumor cells.